PF-Atlas › Clinical Trials › NCT04614441
NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease Who Start Treatment With Nintedanib
OFEV® · Not specified
Registry ID
NCT04614441
Phase
Not specified
Status
Completed
Drug / intervention
OFEV®
Sponsor
Boehringer Ingelheim
Start
2021-01-21
Enrollment
214
Locations
26
About this trial
To better understand the clinical characteristics of Idiopathic Pulmonary Fibrosis (IPF) / Systemic Sclerosis-associated-Interstitial Lung Disease (SSc-ILD)/ Progressive Fibrosing Interstitial Lung Disease (PF-ILD) patients treated with nintedanib and biomarkers associated with the disease course, a non-interventional, 3-year, prospective study will be conducted to collect the long-term real-world clinical data on IPF/SSc-ILD/PF-ILD patients newly administered with nintedanib in Taiwan
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT04614441 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.